Company research / KLRS

Kalaris Therapeutics, Inc. (KLRS)

CIK 0001754068 · Nasdaq · Biological Products, (No Diagnostic Substances)

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Dec 31

For the year ended 2019-12-31, Kalaris Therapeutics, Inc. reported revenue of $165.0K.

Key ratios (year ended 2019-12-31)

-16182.4%
Operating margin
-14447.9%
Net margin

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: 4 · 2026-08-28

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. A dash means a matching observation is unavailable.